Similar articles

• Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.

  Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, Seilhean D, Hauw JJ, Lacomblez L, Loeffler JP, Meininger V. Dupuis L, et al. Neurology. 2008 Mar 25;70(13):1004-9. doi: 10.1212/01.wnl.0000285080.70324.27. Epub 2008 Jan 16. Neurology. 2008. PMID: 18199832
• Re: Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.

  Yoshii Y, Ikeda K, Iwamoto K, Kawase Y, Iwasaki Y. Yoshii Y, et al. Neurology. 2009 Mar 10;72(10):944; author reply 944-5. doi: 10.1212/01.wnl.0000339397.79460.d5. Neurology. 2009. PMID: 19273834 No abstract available.
• Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders.

  Sørensen HT, Riis AH, Lash TL, Pedersen L. Sørensen HT, et al. Circ Cardiovasc Qual Outcomes. 2010 Jul;3(4):413-7. doi: 10.1161/CIRCOUTCOMES.110.936278. Epub 2010 Jun 8. Circ Cardiovasc Qual Outcomes. 2010. PMID: 20530788
• HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.

  Romayne Kurukulasuriya L, Athappan G, Saab G, Whaley Connell A, Sowers JR. Romayne Kurukulasuriya L, et al. Ther Adv Cardiovasc Dis. 2007 Oct;1(1):49-59. doi: 10.1177/1753944707082714. Ther Adv Cardiovasc Dis. 2007. PMID: 19124395 Review.
• Mitochondrial disfunction as a cause of ALS.

  Pizzuti A, Petrucci S. Pizzuti A, et al. Arch Ital Biol. 2011 Mar;149(1):113-9. doi: 10.4449/aib.v149i1.1266. Arch Ital Biol. 2011. PMID: 21412720 Review.